Global MS-Based Proteomics Drug Profiling.

Area of Science:

• Pharmacology
• Proteomics
• Genomics

Background:

• DNA-based technologies like RNAi and gene expression profiling are established for studying drug mechanisms.
• Understanding how cancer cells respond to drugs is crucial for designing combination therapies and predicting toxicity.
• Advances in mass spectrometry (MS) and bioinformatics have made global drug profiling cost-effective and informative.

Purpose of the Study:

• To present MS-based proteomics as a pharmacoproteomics strategy for characterizing drug mechanisms of action.
• To explore the application of this strategy in single drug therapy and multidrug combinations.
• To highlight the potential of integrated proteogenomics for drug target discovery and validation.

Main Methods:

• Utilizing MS-based proteomics to analyze cellular responses to drug treatments.
• Combining MS-based proteomics with other biochemical methods to study regulatory networks and pathways.
• Leveraging proteogenomics analysis, exemplified by The Cancer Genome Atlas program.

Main Results:

• MS-based proteomics provides detailed information on protein translation, degradation, and dynamic regulation.
• This approach reveals insights into regulatory networks, signaling cascades, and metabolic pathways affected by drugs.
• MS-based proteomics can identify single amino acid polymorphisms, protein isoforms, posttranslational modifications, and subcellular localization.

Conclusions:

• MS-based proteomics is a valuable pharmacoproteomics strategy for elucidating drug mechanisms.
• This approach offers a comprehensive understanding of drug effects, including toxicity and pathway modulation.
• Integrated proteogenomics analysis holds significant promise for advancing drug discovery and validation.